PHOENIX--(BUSINESS WIRE)-- Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC: NEOL.PK), a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders and also drug candidates for the treatment of various cancers and other diseases, today announced that Michael L. Babich, President and Chief Operating Officer, will hold a conference call to provide an update on the company’s progress with its various drug product candidates.
The conference call will be held on:
Tuesday, February 15, 2011 @ 4:00 p.m. Eastern/1:00 p.m. Pacific
Domestic: (877) 402-8908
International: (707) 287-9339
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of innovative products that address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders and also drug candidates for the treatment of various cancers and other diseases. Additional information can be obtained by visiting Insys Therapeutic’s web site at www.insysrx.com.
CONTACT:
Insys Therapeutics, Inc.
Michael L. Babich, 602-910-2617
[email protected]
KEYWORDS: United States North America Arizona Illinois
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical
MEDIA: